节点文献

多西他赛联合重组人粒细胞集落刺激因子动员乳腺癌患者外周血干细胞的效果及影响因素分析

Clinical Study on Efficacy of Docetaxel Combined with G-CSF for Mobilization of Peripheral Blood Stem Cell in Metastatic Breast Cancer Patients

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 邵彬余靖邸立军宋国红祝毓琳张洁梁旭车利姜晗昉贾军尤缈宁黄晓蕾王小利周心娜任军张春荣孟松娘杨玉琴高敏黄晓红谢嵘

【Author】 SHAO Bin1,YU Jing1,DI Li-jun1,SONG Guo-hong1,ZHU Yu-lin1,ZHANG Jie1,LIANG Xu1,CHE Li1,JIANG Han-fang1,JIA Jun1,YOU Miao-ning1,HUANG Xiao-lei1,WANG Xiao-li1,ZHOU Xin-na1,REN Jun1,ZHANG Chun-rong2,MENG Song-niang2,YANG Yu-qin2,GAO Min2,HUANG Xiao-hong2,XIE Rong21.Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Breast Cancer Department,Peking University School of Oncology,Beijing Cancer Hospital & Institute Beijing 100142,China,2.Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Transfusion Department

【机构】 北京大学临床肿瘤学院北京肿瘤医院北京市肿瘤防治研究所乳腺内科恶性肿瘤发病机制及转化研究教育部重点实验室北京市肿瘤防治研究所输血科恶性肿瘤发病机制及转化研究教育部重点实验室

【摘要】 目的研究多西他赛联合重组人粒细胞集落刺激因子(rhG-CSF)在乳腺癌患者动员外周血干细胞(peripheral blood stem cell,PBSC)的效果及影响因素。方法 2006年2月—2009年6月我科收治的55例行多西他赛(商品名多帕菲,TXT,120mg/m2持续静脉滴注3h)动员的乳腺癌患者,化疗后白细胞降至1.0×109/L左右时使用rhG-CSF5μg/(kg.d)动员至采集结束。并进一步分析患者年龄、化疗后白细胞最低数、采集前各类血细胞数、内脏、骨转移情况及化、放疗情况对采集单个核细胞(mononuclearcell,MNC)和CD34+细胞的影响。结果多西他赛化疗动员后中位7d白细胞降至1.0×109/L左右,皮下注射rhG-CSF中位3d,采集总MNC平均(5.51±1.24)×108/kg,采集总CD34+细胞平均(2.90±1.38)×106/kg。年龄、化疗后白细胞最低数与采集CD34+细胞均显著相关(P<0.05)。化疗的周期数≤6的患者采集平均CD34+细胞数较周期数≥6患者显著增高(P<0.05)。无1例患者出现严重不良反应。结论 TXT(120mg/m2持续静脉滴注3h)联合rhG-CSF为转移性乳腺癌患者动员的有效安全方案。患者年龄、既往化疗周期数显著影响患者CD34+细胞的采集数量。患者化疗后白细胞最低数可作为采集CD34+细胞数量的预测指标。

【Abstract】 Objective To study the efficacy and factors that affect the efficacy of Doctaxel Combined rhG-CSF for peripheral blood stem cell(PBSC)mobilization for patients with breast cancer.Methods Fifty five patients with breast cancer were included in our study.TXT at the dose of 120 mg/m2 was given continuously for 3 hours.When the number of white blood cell was less than 1.0×109/L,rhG-CSF was given until the end of leukopheresis.CD34+ cells collected by a continuous flow cell separator from peripheral blood were analyzed with FACS.Various elements might affecting the yield of CD34+,including age,the lowest number of leucocyte after chemotherapy,the blood cell count before leukopheresis,visceral or bone metastases,prior chemotherapy and radiotherapy,were analyazed.Results The leukopheresis was started on the median 10th day after mobilization chemotherapy.The mean number of MNC and CD34+ cells were(5.51±1.24)×108/kg and(2.90±1.38)×106/kg respectively.The age and the lowest number of leucocyte were related with CD34+ cells number.The CD34+ cells number was higher in patients with the cycles of chemotherapy less than or equal to 6 than that in the matched group(P<0.05).No serious adverse side effect was observed.Conclusion TXT plus rhG-CSF was an effective and safe mobilization regimen for autologous peripheral blood stem progenitor cells in patients with breast cancer.The age and prior chemotherapy cycles affected the number of CD34+ cells collected.The lowest number of leucocyte may be a good predictor of CD34+ cells collected.

  • 【文献出处】 肿瘤防治研究 ,Cancer Research on Prevention and Treatment , 编辑部邮箱 ,2011年06期
  • 【分类号】R969.4
  • 【下载频次】149
节点文献中: 

本文链接的文献网络图示:

本文的引文网络